Oric Pharmaceuticals (ORIC) revenue and earnings history
Oric Pharmaceuticals's annual figures for 8 fiscal years, as filed with the SEC.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$143M | −$129M | −$111M | $712K | −$112M | $25M | — | — | $45.7M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Oric Pharmaceuticals (ORIC) on OQRO.
Common questions
Has Oric Pharmaceuticals been profitable?
It reported a net loss in 8 of the years shown (2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$21.4M in fiscal 2018.
What was Oric Pharmaceuticals's free cash flow in fiscal 2025?
−$112M: operating cash flow of −$111M minus capital expenditure of $712K. OQRO calculates free cash flow this way from the two filed lines.
Does Oric Pharmaceuticals buy back shares or pay dividends?
None of the 8 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Oric Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.